Crinetics Pharmaceuticals Inc Palsonify FDA Approval Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Congrats on the approval. I guess what do you think it may take to gain traction in surgically naive patients? Do you plan on running additional trials to expand the label? Do you think the current crafting of the label gives you some meaningful inroads into that population? And then separately, for those patients who are not diagnosed, how do you think about a targeted campaign to find them?

Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst : Looking forward to the launch updates.

Question: Yasmeen Rahimi - Piper Jaffray Inc - Analyst : Congrats on an incredible accomplishment and what a wonderful label that you received. I guess the question, given that acromegaly questionnaire is part of the clinical section, it would be great if you could talk about how your sales team could speak to patients and physicians around a therapy that's available that really cuts through breakthrough therapies that is one of the challenging symptomologies of the disease to feel good for three weeks and lousy in your fourth week. Could you maybe talk about how that could be utilized that that's going to be a big driver of utility of PALSONIFY beyond just being highly effective and safe in an oral option?

Question: Yasmeen Rahimi - Piper Jaffray Inc - Analyst : And if I may ask one question from Toby. Toby, moving forward into the upcoming quarters, what metrics do you hope to share with us as we are going to be monitoring the launch closely?

Question: Gavin Clark-Gartner - Evercore Inc - Analyst : Congrats on the approval. So just on the pricing side, I'm currently calculating that Somatuline and Sandostatin net price is probably in the $60,000 to $70,000 range, give or take, depending on dose after all the rebating and discounting. But the Signifor LAR WACC price is pretty closely aligned with what you noted, and it seems like without that much rebating. So I'm wondering what quality of access does Signifor have in acromegaly relative to the SRLs at a higher price? And what are your own expectations on gross to net?

Question: Joseph Schwartz - Leerink Partners LLC - Analyst : Great. Let me add my congrats as well. First, I was just wondering, to what extent do you expect physicians to trial PALSONIFY in their own practices on a relatively limited basis so they can get experience with how it performs in their own hands? We see this dynamic play out sometimes, yet here, it seems like the decision could be relatively straightforward. So I was wondering if we could get your thoughts on potential adoption patterns in the real world.

Question: Joseph Schwartz - Leerink Partners LLC - Analyst : That actually anticipated my second question.

Question: Brian Skorney - Robert W. Baird & Co Inc - Analyst : Congrats on PALSONIFY's approval, big day. I'm sorry if I missed this on the $290,000 number, but you have two different NDCs. Are they both the same price? Or like is it $24,000 per 60 tablet bottle for each? Or do they have two different prices? And if so, could you break out the list by NDC? And then on the 60/30/10 breakdown, for commercial Medicare, Medicaid payer mix. Is that in the active treatment segment or the actively managed segment? Just wondering if those injectables might have a higher commercial representation and treatment naive, maybe higher Medicaid representation or if you could just give some better on-the-ground insight there. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 25, 2025 / 10:00PM, CRNX.OQ - Crinetics Pharmaceuticals Inc Palsonify FDA Approval Call

Question: Douglas Tsao - H C Wainwright & Co LLC - Analyst : Congrats on the approval. It's been a great journey for you, Scott. Just maybe a question for Isabel. I'm just curious, when we think about the launch, where do you expect to see the greatest adoption early going? I assume -- or where will you be focusing most of your efforts? Will it be largely on pituitary centers? And how long do you think it will take before you start to see adoption in the broader community setting? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 25, 2025 / 10:00PM, CRNX.OQ - Crinetics Pharmaceuticals Inc Palsonify FDA Approval Call

Question: Douglas Tsao - H C Wainwright & Co LLC - Analyst : Okay. Great. Isabel, just a follow-up in terms of your -- the program to get drug to patients within 48 hours, will you be able to complete benefit adjudication in that time? Or will there be some amount of being at risk in terms of shipping drug to patients?

Question: Douglas Tsao - H C Wainwright & Co LLC - Analyst : Isabel, should we think of that to some extent as sort of in lieu of the sampling program sort of like a starter path?

Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst : Congrats to Scott and the team on just a really well-executed program from start to finish. My question is a little bit on -- so in doing my market research, one thing that I saw was that the number of patients controlled after surgery is variable from center to center. And I was wondering, a, is this what you've seen in your market research? And b, have there been advances in surgical techniques or anything that might then impact the number of patients who are not biochemically controlled after surgery and therefore, the market opportunity?

Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst : And just to ask again, has it -- have you seen any trends in recent years or it kind of held steady across the board?

Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst : Congrats again.